• Home
  • Social Media Team
    • Jack Aiello
    • Sheri Baker
    • Yelak Biru
    • Cynthia Chmielewski
    • John DeFlice
    • Linda Huguelet
    • Teresa Miceli
    • Jim Omel
    • Valarie Traynham
    • Michael Tuohy
    • Robin Tuohy
    • Tiffany Williams
  • ASH Abstracts
  • IMF Website
IMF logo

MENU
  • Home
  • Social Media Team
    • Jack Aiello
    • Sheri Baker
    • Yelak Biru
    • Cynthia Chmielewski
    • John DeFlice
    • Linda Huguelet
    • Teresa Miceli
    • Jim Omel
    • Valarie Traynham
    • Michael Tuohy
    • Robin Tuohy
    • Tiffany Williams
  • ASH Abstracts
  • IMF Website

Yelak Biru

Diagnosed at the young age of 25 with stage III multiple myeloma, Yelak Biru is a patient turned myeloma research advocate. Working with a team of medical practitioners and educating himself through support group leadership, information resources, advocacy sites, social media, and the IMF, Yelak has successfully integrated myeloma to his life for over two decades.

Follow Yelak on Twitter
0

ASH20, a Time of Hope at the End of HORRENDOUS 2020.

Jim Omel, Uncategorized | December 11, 2020

As I write this, the USA has surpassed 3,100 COVID deaths in one day. This horrendous reality now means more Americans die each day than were lost on 9/11/2001. Many more of us die each day than Dec 7, 1941 Pearl Harbor day. We now sadly lose nearly the same number of dead Americans every […]

Read More
 
  • Recent Posts

    • The Times Are Changing – ASH Wrap
    • Virtual ASH 20 — More Than I Could Have Imagined
    • Never, Ever Give Up
    • Hope for the Future
    • ASH 2020 in a COVID-19 World, A Virtual Experience
  • IMF Social Media Team

    • Jack Aiello
    • Sheri Baker
    • Yelak Biru
    • Cynthia Chmielewski
    • John DeFlice
    • Linda Huguelet
    • Teresa Miceli
    • Jim Omel
    • Valarie Traynham
    • Michael Tuohy
    • Robin Tuohy
    • Tiffany Williams
  • Most Searched Terms

    ADC antibody drug conjugates APOLLO belantamab mafodotin bispecific antibody BiTES CAR t-cell therapy CARTITUDE clinical trial coronavirus vaccine covid-19 covid-19 vaccine daratumumab Dr. Fauci EMN02/HO95 FORTE frontline treatment Griffin Trial hope IFM 2009 Trial immunotherapy IMWG International Myeloma Working Group isatuximab maintenance melflufen minimal residual disease monoclonal antibody myeloma nurse myeloma specialist pandemic progression-free survival quality of life refractory relapse satellite symposium smoldering multiple myeloma survivorship SWOG trial talquetamab teclistamab TOURMALINE treatment algoritm treatment sequencing twitter activity
 

THIS WEBSITE IS HOSTED BY THE INTERNATIONAL MYELOMA FOUNDATION ("IMF") FOR MULTIPLE MYELOMA SUPPORT GROUPS. THE CONTENT APPEARING ON THIS WEBPAGE IS NOT CONTROLLED OR PROVIDED BY IMF, AND IMF NEITHER WARRANTS NOR GUARANTEES THE ACCURACY OF SUCH CONTENT. THE FOREGOING NOTWITHSTANDING, THE CONTENT IS NOT A SUBSTITUTE FOR ADVICE AND SERVICE PROVIDED BY QUALIFIED AND LICENSED MEDICAL PROFESSIONALS, AND SHOULD NOT BE RELIED ON WITH RESPECT TO ANY HEALTH MATTERS. ANY HEALTH-RELATED INFORMATION FOUND HEREIN IS ONLY MADE AVAILABLE AS PART OF A GENERAL EDUCATIONAL SERVICE.

 

with support from: